May. 5 at 5:48 AM
$KZIA $CELC Celcuity estimate up to
$3B PA sales for gedatolisib, in breast cancer - these earnings are in line with consensus.
$2.5B revenues equates to
$1.5 B net and on an industry multiply (patents out to 2042), values the company at
$20 B. Their success, in hard-to-treat PIK3CA cancer, changes the treatment paradiam. No longer may the oncologist say to the patient - you have 2 months.... Brian Sullivan post market close Friday, alluded to expanding the drug into other cancer types. Most cancers have PIK3CA mutations - prevalent in 10 to 30% of cases. Breast cancer sales can multiple 10 times as FDA Phase 2/3 registrational studies complete in other cancers.
$35 billion sales PA cancer drug, Keytruda has undertaken 45 late-stage trials. Alternatively, the company may accept a bid of
$25B in 12 months. These are the simple facts of the matter. After
$4B research spend by many, over 20 years, - the complexities and rewards of the PI3K pathway have been finally unlocked.
